The biopharma industry stands at the crossroads of innovation and necessity as it leans into the burgeoning field of immunology. With the global immunology market anticipated to grow exponentially in the coming years, reaching numbers second only to oncology, major players and emerging startups
In a bold move that underscores its commitment to oncology and global expansion, Japan-based Ono Pharmaceutical Co., Ltd. has finalized its acquisition of Deciphera Pharmaceuticals Inc., a U.S. biopharmaceutical firm specializing in cancer treatments. The transaction was settled with the purchase
Throughout 2023 and 2024, the U.S. Food and Drug Administration (FDA) played a pivotal role in the pharmaceutical and biotechnology sectors, not only by approving a significant number of new drugs but also by pushing the boundaries of innovation. These two years were marked by a notable surge in
The pharmaceutical landscape is witnessing a dynamic shift as companies like Contract Pharmaceuticals Limited (CPL) embrace new ownership structures aimed at invigorating their strategic direction. When a company of CPL's stature undergoes significant change, it signals to the industry
The landscape of medical treatment and drug development is experiencing a new dawn as the U.S. Food and Drug Administration (FDA) plays a pivotal role in ushering in an era where the once unimaginable becomes reality. With a discerning eye on cutting-edge therapies, especially in gene therapy and
In the rapidly advancing field of nuclear radiation therapy, a groundbreaking treatment is emerging, promising to redefine the landscape of medical response to nuclear events. Financed by the backing of a weighty $4.2 million agreement with the National Institute of Allergy and Infectious Diseases
